Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus VEETIDS 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN AND SULBACTAM versus VEETIDS 125.
AMPICILLIN AND SULBACTAM vs VEETIDS '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity. Sulbactam is a β-lactamase inhibitor that irreversibly inhibits a broad range of β-lactamases, preventing degradation of ampicillin.
VEETIDS '125' (presumed to be a formulation containing penicillin V potassium) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
1.5-3 g (ampicillin 1-2 g + sulbactam 0.5-1 g) IV/IM every 6 hours. Maximum daily dose of sulbactam is 4 g.
125 mg orally twice daily for 5-10 days.
None Documented
None Documented
Ampicillin: 1-1.8 hours; sulbactam: 1-1.5 hours. Prolonged in renal impairment (e.g., creatinine clearance <30 mL/min: up to 8-12 hours).
2-4 hours in patients with normal renal function (CrCl >80 mL/min); prolonged to 20-40 hours in anuria. Clinical note: dosing interval must be adjusted based on creatinine clearance to avoid accumulation.
Primarily renal (70-75% unchanged ampicillin, 75-80% unchanged sulbactam). Biliary excretion accounts for ~25% of ampicillin and ~20% of sulbactam. Fecal elimination is minor (<5%).
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic